---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-044838"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T14:11:59.621940+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma Q1 2025 net loss $5.3M; cash $29.9M; NXP900 Phase 1b advancing

## Summary
- Cash and equivalents $29.9M as of Mar 31, 2025, up from $18.5M at Dec 31, 2024, driven by $14.0M net public offering proceeds.
- Net loss $5.3M for Q1 2025 vs $4.2M in Q1 2024; R&D expenses $3.7M, G&A $1.9M.
- NXP900 Phase 1a data at AACR showed robust pharmacodynamic response; Phase 1b enrollment in specific genetic alterations pending.
- NXP800 Phase 1b study in ARID1a-mutated ovarian cancer enrolling; update expected in two months.
- Completed $15.5M financing extending projected cash runway into Q1 2027.

## SEC filing metadata
- accession: 0001104659-25-044838
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465925044838/0001104659-25-044838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465925044838/tm2514104d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-044838
- JSON: https://secwatch.observer/filing/0001104659-25-044838.json
- Plain text: https://secwatch.observer/filing/0001104659-25-044838.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.